Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Gadopentetate dimeglumine
- drug: Gadofosveset
- drug: Gadobutrol
- procedure: Bone scan
- procedure: Positron Emission Tomography (PET) scan
- drug: 18F-Fludeoxyglucose (18F-FDG)
- procedure: Computed Tomography (CT) scan
- drug: 18F-Sodium Fluoride (18F-NaF)
- procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scan
- drug: 99mTc-methyl diphosphonate
Eligibility
All patients were enrolled after receiving a regular medical care bone scan using the
radiolabel 99mTc-methyl diphosphonate (t99-MDP).
INCLUSION CRITERIA
- ≥ 18 years old at the time of the drug administration
- ≥ Stage 3 breast cancer OR ≥ stage 2 prostate cancer OR prostate-specific antigen
(PSA) > 10 micrograms/L OR recurrent breast or prostate cancer
- Capable of complying with study procedures
- Able to remain still for duration of imaging procedure (about one hour)
- Written informed consent
EXCLUSION CRITERIA
- Pregnant or nursing
- Metallic implants that contraindicate MRI
- Renal function impairment that contraindicates MRI
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.